Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer.

Löfling, Lukas; Sundström, Anders; Kieler, Helle; Bahmanyar, Shahram; Linder, Marie

Löfling, Lukas; Sundström, Anders; Kieler, Helle; Bahmanyar, Shahram; Linder, Marie.

Afiliação

Löfling L; Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden, lukas.lofling@ki.se.
Sundström A; Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden, lukas.lofling@ki.se.
Kieler H; Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden, lukas.lofling@ki.se.
Bahmanyar S; Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden, lukas.lofling@ki.se.
Linder M; Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden, lukas.lofling@ki.se.

Clin Epidemiol ; 11: 133-143, 2019.

Article em En | MEDLINE | ID: mdl-30774448

Palavras-chave

antimuscarinic medications; colon cancer; lung cancer; overactive bladder

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google